1. A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. (January 2019) Authors: Vidimar, Vania; Licona, Cynthia; Cerón-Camacho, Ricardo; Guerin, Eric; Coliat, Pierre; Venkatasamy, Aina; Ali, Moussa; Guenot, Dominique; Le Lagadec, Ronan; Jung, Alain C.; Freund, Jean-Noel; Pfeffer, Michel; Mellitzer, Georg; Sava, Gianni; Gaiddon, Christian Journal: Cancer letters Issue: Volume 440-441(2019) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms. Issue 3 (9th December 2019) Authors: Licona, Cynthia; Delhorme, Jean-Baptiste; Riegel, Gilles; Vidimar, Vania; Cerón-Camacho, Ricardo; Boff, Bastien; Venkatasamy, Aina; Tomasetto, Catherine; da Silva Figueiredo Celestino Gomes, Priscila; Rognan, Didier; Freund, Jean-Noel; Le Lagadec, Ronan; Pfeffer, Michel; Gross, Isabelle; Mellitze... Journal: Inorganic chemistry frontiers Issue: Volume 7:Issue 3(2020) Page Start: 678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance. Issue 7 (15th March 2016) Authors: Chow, Mun Juinn; Licona, Cynthia; Pastorin, Giorgia; Mellitzer, Georg; Ang, Wee Han; Gaiddon, Christian Journal: Chemical science Issue: Volume 7:Issue 7(2016:Jul.) Page Start: 4117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗